Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Objective This study assessed the efficacy and safety of a 14-day treatment course of once-daily zuranolone 50 mg, an investigational oral positive allosteric modulator of the γ-aminobutyric acid type A (GABA A ) receptor, for the treatment of major depressive disorder. Methods Patients 18-64 years of age with severe major depressive disorder were enrolled in this randomized, double-blind, placebo-controlled trial. Patients self-administered zuranolone 50 mg or placebo once daily for 14 days. The primary endpoint was change from baseline in total score on the 17-item Hamilton Depression Rating Scale (HAM-D) at day 15. Safety and tolerability were assessed by incidence of adverse events. Results Of 543 randomized patients, 534 (266 in the zuranolone group, 268 in the placebo group) constituted the full analysis set. Compared with patients in the placebo group, patients in the zuranolone group demonstrated a statistically significant improvement in depressive symptoms at day 15 (least squares mean change from baseline HAM-D score, -14.1 vs. -12.3). Numerically greater improvements in depressive symptoms for zuranolone versus placebo were observed by day 3 (least squares mean change from baseline HAM-D score, -9.8 vs. -6.8), which were sustained at all visits throughout the treatment and follow-up periods of the study (through day 42, with the difference remaining nominally significant through day 12). Two patients in each group experienced a serious adverse event; nine patients…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recently published phase III trial had very positive results, showing significant clinical improvements at day 3 and sustained through the whole duration of the study at day 42 [189].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [189]
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Self-citationRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19686 · Cited by 2,138
Mokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Yan, C.-G., Chen, X., Li, L., Castellanos, F. X., Bai, T.-J., Bo, Q.-J., Cao, J., Chen, G.-M., Chen, N.-X., Chen, W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900390116 · Cited by 895
Research works printed but not linked: 4
- Keks N, 2016, Aust Prescr, 39, 76
- 10.1016/j.biopsych.2021.07.017 · doi:10.1016/j.biopsych.2021.07.017
- Rapaport MH, 2006, Psychiatry (Edgmont), 3, 50
- Ogawa Y, 2019, Cochrane Database Syst Rev, 6, CD001026
Cited by
Zuranolone for the Treatment of Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., et al. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220785 · Cited by 192
Self-citationCutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 194
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01728-8 · Cited by 104
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“A recently published phase III trial had very positive results, showing significant clinical improvements at day 3 and sustained through the whole duration of the study at day 42 [189].”
BackgroundCorreia, A. S., & Vale, N. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4010010 · Cited by 58
Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
Marecki, R., Kałuska, J., Kolanek, A., Hakało, D., & Waszkiewicz, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1298359 · Cited by 39
Lei, L., Wang, Y., Chen, C.-Y., Wang, Y., & Zhang, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122988 · Cited by 40
Heo, Y. (2023) · Drugs · doi:10.1007/s40265-023-01953-x · Cited by 38
Parikh, S. V., Aaronson, S. T., Mathew, S. J., Alva, G., DeBattista, C., Kanes, S., Lasser, R. A., Bullock, A. E., Kotecha, M., Jung, J., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01751-9 · Cited by 38
Self-citationImplementing Precision Medicine in Psychiatry
Cevoli, F., Manji, H. K., Miller, A. H., Penninx, B. W. J. H., Kas, M. J., Pariante, C. M., Picker, L. D., Świeboda, P., & Leboyer, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3562 · Cited by 26
Lin, Y., Tu, Y., Hung, K., Liang, C., Tseng, P., Lin, P., Lai, E. C., & Hsu, C. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102308 · Cited by 26
Li, Z., Wu, Q., Peng, P., Wu, M., Liu, S., & Liu, T. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115640 · Cited by 26
Deligiannidis, K. M., Bullock, A. E., Nandy, I. M., Dunbar, J., Lasser, R. A., Witte, M. M., Leclair, B., & Wald, J. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001873 · Cited by 27
Self-citationA comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 25
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Moss, L., Laudenslager, M., Steffen, K. J., Sockalingam, S., & Coughlin, J. W. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00598-5 · Cited by 23
“A similar nonsignificant weight trend was observed in a recent trial examining zuranolone, a newly approved medication for the treat-ment of postpartum depression that functions as a positive allosteric modulator of synaptic and extrasynaptic GABA A receptors [67, 69].”
Etkin, A., Powell, J. J., & Savitz, A. J. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01970-8 · Cited by 26
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 25
“Although zuranolone, either as a monotherapy or when co-initiated with an ADM, demonstrated efficacy in non-TRD MDD patients [129–132], the FDA in 2023 declined to give marketing approval for zuranolone for the treatment of MDD, citing both efficacy and safety concerns [129].”
Clayton, A. H., Suthoff, E. D., Jain, R., Kosinski, M. R., Fridman, M., Deligiannidis, K. M., Meltzer-Brody, S. E., Chen, S., Gervitz, L. M., Huang, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.268 · Cited by 18
Self-citationZou, J., Yang, L., Yang, G., & Gao, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115450 · Cited by 18
New and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 20
Sackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Ozpolat, M. C., Okcay, Y., Ulusoy, K. G., & Yıldız, O. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03818-6 · Cited by 15
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Cutler, A. J., Mattingly, G. W., Kornstein, S. G., Aaronson, S. T., Lasser, R. A., Zhang, H., Rana, N., Brown, C., Levin, S. N., Miller, C., et al. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m14845 · Cited by 15
Self-citationWinslow, M., White, E., Rose, S. J., Salzer, E. A. J., & Nemec, E. C. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01714-0 · Cited by 16
“Participants on antidepressants prior to the study were permitted if they were on a stable regimen for at least 60 days [19, 24], or 30 days [23, 25, 26] in which doses could not be titrated during the active trial.”
InfluentialA Critical View on New and Future Antidepressants
Serretti, A. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1145 · Cited by 13
Raja, A., Ahmed, S., Siddiqui, M. B. A., Mir, S. L., Kumar, R., Ahmed, M. M., Raja, S., Amin, S. B., Rahman, H. A. U., Deepak, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1425295 · Cited by 15
Clinical Utility of Zuranolone for Postpartum Depression: A Narrative Review
Giannopoulos, A., Singh, J., & Deligiannidis, K. M. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s466260 · Cited by 15
Riebel, M., Brunner, L.-M., Nothdurfter, C., Wein, S., Schwarzbach, J. V., Lière, P., Schumacher, M., & Rupprecht, R. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01843-7 · Cited by 12
Kato, M., Nakagome, K., Baba, T., Sonoyama, T., Fukuju, H., Shimizu, R., Gomez, J. C., Motomiya, T., & Inoue, T. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13917 · Cited by 12
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
“In multiple trials in depression, it was superior to placebo by day 3 but the ability to continue to separate at 15 days has been inconsistent and appears to be in part dose related — i.e., 50 mg per day appears to be more effective overall than does 30 mg [14, 15].”
BackgroundInfluentialQiu, Y., Tao, Y., Duan, A., Wei, X., Wang, M., Xie, M., Chen, Z., Shang, J., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1334694 · Cited by 9
Understanding and treating postpartum depression: a narrative review
Cardaci, V., Carminati, M., Tondello, M., Pecorino, B., Serretti, A., & Zanardi, R. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000560 · Cited by 9
“…or adjunct therapy) for adults with MDD with different randomized, double-blind, placebo-controlled trial demonstrating rapid improvement in depressive and anxiety symptoms compared with placebo (Arnaud and Bonthapally, 2022; Clayton et al ., 2023; Lin et al ., 2023; Parikh et al ., 2024).”
Neurosteroid treatment of postpartum depression and beyond
Deligiannidis, K. M., & Meltzer-Brody, S. E. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.90 · Cited by 8
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
“In a phase-3 randomized controlled trial, a two-week course of zuranolone 50 mg once daily was sufficient to induce and maintain symptomatic relief for at least six weeks, simplifying long-term management and expanding the neurosteroid class beyond intravenous brexanolone [199].”
Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis
Ahmad, A., Awan, A. R., Nadeem, N., Javed, A. S., Farooqi, M., Daniyal, M., & Mumtaz, H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1361692 · Cited by 9
Haris, M., Mukhtar, S., Mohiuddin, M., Amir, S., Laique, F., Azam, M. M., & Giri, B. (2025) · Health Science Reports · doi:10.1002/hsr2.70513 · Cited by 7
“In the first study, patients were administered 50 mg of zuranolone or a placebo once daily in the evening for a duration of 14 days [43].”
InfluentialEfficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
Wang, S., Zhang, W., Liu, Z., Zhang, T., Wang, Y., & Li, W. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1332329 · Cited by 9
Bhatti, N. A., Jobilal, A., Asif, K., Villegas, M. J., Pandey, P., Tahir, A. N., Balla, N. V. D. B., Camargo, M. P. A., Ahmad, S., Kataria, J., et al. (2023) · Cureus · doi:10.7759/cureus.44038 · Cited by 8
Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
Pine, D. S. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230537 · Cited by 6
Peripartum Depression Pharmacotherapies Targeting GABA–Glutamate Neurotransmission
Courtes, A. C., Smitherman, L., Shahani, L., Soares, J. C., Goetzl, L. M., & Machado‐Vieira, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176177 · Cited by 5
“In the WATERFALL study examining MDD treatment, 50 mg zuranolone demonstrated significant improvements in depressive symptoms by day 15 compared to placebo [52].”
Moloney, R. A., Pavy, C. L., Kahl, R. G. S., Palliser, H. K., Hirst, J. J., & Shaw, J. C. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00957-5 · Cited by 5
Xu, Y., Mortensen, M., Liebowitz, S., Jensen, N. N., Tian, Y., Bavo, F., Seidel, T., Smart, T. G., & Frølund, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02881 · Cited by 4
Hirst, J. J., Palliser, H. K., Pavy, C. L., Shaw, J. C., & Moloney, R. A. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101169 · Cited by 4
The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
Petrescu, B. M., Marinescu, I. P., Marinescu, D., Vasiliu, O., Mangalagiu, A. G., & Cândea, C. A. (2023) · Psihiatru ro · doi:10.26416/psih.75.4.2023.8926 · Cited by 4
The pharmacological management of treatment-resistant depression: what does the future hold?
Serretti, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2287011 · Cited by 4
Cha, D. S., Kleine, N., Teopiz, K. M., Vincenzo, J. D. D., Ho, R., Galibert, S. L., Samra, A., Zilm, S. P. M., Cha, R. H., d’Andrea, G., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2298340 · Cited by 4
“Moreover, it was noted that there was a greater improvement in depressive symptoms for zuranolone versus placebo, numerically, as early as Day 3 (least squares mean change from baseline HAM-D score, −9.8 vs. −6.8) and this observation was sustained throughout treatment and follow-up at Day 42 [25].”
BackgroundMethodInfluentialRapid-Acting Treatments for Perinatal Depression: Clinical Landscapes and Future Horizons
Beydler, E. M., Koire, A. M., Steuber, E. R., Taylor, J. J., & Mergler, R. J. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22040546 · Cited by 4
“At 45-day follow-up, 40% of patients were in remission [9].”
Endocrinological Treatment Targets for Depressive Disorder
Yoon, S., & Kim, Y. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_1 · Cited by 3
Current Developments in the Treatment of Postpartum Depression: Zuranolone
Sönmez, D., & Hocaoğlu, Ç. (2024) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2024.24409 · Cited by 4
Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder
Liu, J., Hong, L.-M., Qian, Y., Chen, R., & Lin, W.-W. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120158 · Cited by 2
Durability of zuranolone in postpartum depression versus major depressive disorder
Terao, I. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.70011 · Cited by 2
Towards precision psychiatry: initial foundations and future directions
Etkin, A., O’Donnell, P., Ressler, K. J., & Manji, H. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01509-0 · Cited by 3
“By contrast, multiple large and similarly designed phase III trials in MDD failed to show sustained efficacy of zuranolone 27–30 .”
Longitudinal Analysis in Maternal Mental Health Research
Dziadkowiec, O. (2024) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1016/j.jogn.2024.11.006 · Cited by 2
Abdelazim, A. H., Abduljabbar, M. H., Alnemari, R. M., Alaqel, S. L., Alosaimi, M. E., Althobaiti, Y. S., Alzhrani, R. M., & Almalki, A. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-07726-8 · Cited by 2
Akram, A. S., Sarwar, R., Zafar, M. F., Umair, M., Ullah, I., & Nazir, A. (2023) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000345 · Cited by 2
Pharmakotherapie, Psychotherapie oder „Superplacebos“? Wirkmechanismen der Therapie mit Psychedelika
Gründer, G., Brand, M., Färber, L. V., Kärtner, L., Kunz, L. C., Rohrmoser, B., Scharf, D., Schmitz, C. N., Spangemacher, M., & Mertens, L. J. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00709-6 · Cited by 2
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4734-2 · Cited by 2
Application of Treatment Response Biomarkers from Major Depression to Perinatal Depression
Kwok, W. Y., Wagner-Schuman, M. L., Eisenlohr-Moul, T. A., & Hage, B. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120607 · Cited by 1
“Trials have also been conducted for treatment with zuranolone in MDD. Phase three randomized clinical trials demonstrated mixed results, and it has yet to be FDA-approved for MDD outside of the perinatal period [127,128].”
Assessing the utility of the neurosteroid zuranolone to modify alcohol-related behaviours
Ursich, L. T., Pearl, A. J., Maddern, X. J., Lawrence, A. J., & Walker, L. C. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110833 · Cited by 1
Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives
Cuomo, A., Pinzi, M., & Fagiolini, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634195 · Cited by 1
“…with major depressive disorder, a 14-day course of zuranolone (50 mg/day) resulted in significantly greater reductions in depressive symptoms compared with placebo by Day 15 (mean HAM-D reduction approximately 14.1 vs 12.3 points), with a rapid onset of effect evident as early as Day 3 [38,39].”
InfluentialWorthington, R., Aftab, Z., Leong, N., & Alexander, J. T. (2026) · Cleveland Clinic journal of medicine · doi:10.3949/ccjm.93a.25052
New Antidepressant Development in the Treatment of Depression
Spiti, A., Caldirola, D., & Perna, G. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_23 · Cited by 2
Kalin, N. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230565
Can a novel, rapid-acting oral treatment effectively manage PPD?
Pauli, J. M. (2023) · OBG Management · doi:10.12788/obgm.0310
Gillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00006-5
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Pharmacotherapy of postpartum depression: An update
Kumar, K., Pallavi, K., Martand, K., & Maharshi, V. (2025) · Indian Journal of Obstetrics and Gynecology Research · doi:10.18231/j.ijogr.2025.001 · Cited by 1
Jiang, Y. B., Chen, Y., Zheng, R., Zhou, B., Wei, Y., Li, S., Han, S., Zhang, Y., & Cheng, J. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111330
Umer, M., Zaheer, Z., & Naveed, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06776-0
“Firstly, the authors used the study by Clayton et al. that involves two different treatment groups i.e. 20 mg zuranolone and 30 mg zuranolone with a single comparator placebo group (Clayton et al. 2023).”
Effects of antidepressants on weight: mechanisms, clinical effects, and management strategies
Bairamalov, V. A., Dautova, V. A., Bakhareva, M. D., Mariams, A. S. Z., Alyeva, L. R., Ismikhanov, M. M., Gazizova, A. I., Zorina, N. A., Malinina, Y. A., Vedernikova, V. V., et al. (2025) · Russian Medicine · doi:10.17816/medjrf675281
Zuranolone in Palliative Care: Promise and Practicality for the Rapid Treatment of Depression
Prommer, E. (2025) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091251348176
“22 The CORAL study (endpoint was the change in HAM-D score at 3 days) evaluated zuranolone 50 mg plus antidepressant therapy vs placebo plus antidepressant treatment for 14 days.”
ADVANCES IN TREATING DEPRESSION
Director of Pharmacy (retd.), S. J. C. M. H. S., & Tutupalli, L. V. (2025) · INDIAN DRUGS · doi:10.53879/id.62.06.15334
Editor’s Pick: Seaport Therapeutics
Garber, K. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02792-9
Chen, L., Fu, B., Liu, J., Wang, C., Huang, W., Yuan, D., Qing, C., Zhang, Y., & Hong, H. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70647
Alqahtani, A. S., Abduljabbar, M. H., Alnemari, R. M., Abdelazim, A. H., & Almalki, A. H. (2025) · Luminescence · doi:10.1002/bio.70381
New drugs for postpartum depression: brexanolone and zuranolone
Rupiński, P., & Pietras, T. (2026) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2025.0042 · Cited by 1
A Nonsteroidal Reversal Agent Inhibits Allopregnanolone Modulation of α1β3δ GABA A ReceptorsPreprint
Zhou, X., Jounaïdi, Y., & Miller, K. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.718525
Insan, S., Gilles, M., & Spangemacher, M. (2026) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-026-6703-2
“Darüber hinaus deuten Daten zur Behandlung der Major Depression auf eine vorübergehende antidepressive Wirkung Zuranolons hin: Der Wirkeintritt erfolgt rasch (nach circa zwei Wochen), jedoch scheint die Wirkung nicht zu überdauern [27, 36].”
Yang, X., Chen, C.-Y., Wang, Y.-F., & Zhang, Y. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111826
Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response
Serretti, A. (2026) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.26.1487
“…and existential dimensions of recovery, at the cost of a resource-intensive psychological intervention and un-resolved questions about blinding and scalability; extended-release ketamine formulations attack the pharmacokinetic drivers of dissociation and possibly abuse liability [85,88,90,93].”
The Gut–Brain Axis in Ganoderma lucidum’s Antidepressant Effects in Cancer Comorbidity: A Review
Du, X.-Y., Bu, F., & Ling, Z. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101731
Sugimori, Y., Yano, Y., Asano, T., Suzuki, S., Kaigawa, T., Yokose, J., Shigetsura, Y., Muramatsu, S., & Nitta, A. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111148
King, A., Hardy, M. S., Rhee, T. G., & Wilkinson, S. T. (2026) · CNS Drugs · doi:10.1007/s40263-026-01330-8
“Similarly, brexanolone and zuranolone, γ-aminobutyric acid (GABA)-A-receptor-positive allosteric modulators, were approved for postpartum depression [8, 9].”
Evaluating seltorexant as a treatment option for major depressive disorder
Nicola, M. D., Pepe, M., Marcelli, I., Panaccione, I., & Sani, G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2717199
“Zuranolone, a GABAA-receptor positive allosteric modulator approved for postpartum depression, has reported mixed phase 3 data in MDD with one positive trial (WATERFALL) [49] and one negative trial (MOUNTAIN) [50].”
The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics
Radonjić, N. V., Moon, K. C., & Deligiannidis, K. M. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70253
Profiling zuranolone as a treatment option for postpartum depression
Gonzalez‐Torres, C., & Sharma, V. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2733192
Interconnecting diagnostic progress and management techniques in depression: A narrative review
Mahrous, A., Hashim, H., Gaafar, M., Alatas, H., Ibrahim, A., Kheir, M., & Hetta, M. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45571
Xu, H., Zhang, S., He, H., Zhao, X., Cheng, Y., Wang, Y., Li, J., Yu, Y., Bian, Y., Guo, Y., et al. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71395
“[87], a phenomenon not observed in PPD patients [88].”
Hu, H., Lee, Y., Yuan, P., Yavi, M., Park, L., Kvarta, M. D., & Zarate, C. A. (2026) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2026.100391
Metadata
- Authors
- Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- American Journal of Psychiatry
- Published
- 2023-09-01
- Volume
- 180
- Issue
- 9
- Pages
- 676-684
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4367834204
- Cited by
- 87
- References
- 38
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 24 · 2023: 19
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- zuranolone, major depressive disorder, 5α-reductase inhibition, antidepressant efficacy, adverse events, tolerability
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Humans, Pregnanes, Pregnanolone, Pyrazoles, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.